Improved PIEZO1 agonism through 4‐benzoic acid modification of Yoda1

Gregory Parsonage,Kevin Cuthbertson,Naima Endesh,Nicoletta Murciano,Adam J. Hyman,Charlotte H. Revill,Oleksandr V. Povstyan,Eulashini Chuntharpursat‐Bon,Marjolaine Debant,Melanie J. Ludlow,T. Simon Futers,Laeticia Lichtenstein,Jacob A. Kinsella,Fiona Bartoli,Maria Giustina Rotordam,Nadine Becker,Andrea Brüggemann,Richard Foster,David J. Beech
DOI: https://doi.org/10.1111/bph.15996
IF: 7.3
2022-12-03
British Journal of Pharmacology
Abstract:Background and Purpose PIEZO1 forms mechanically activated calcium‐permeable non‐selective cation channels in numerous species and cell types. Options for pharmacological modulation are limited and so we modified a PIEZO1 small‐molecule agonist (Yoda1) to advance capability for modulation. Experimental Approach Medicinal chemistry generated Yoda1 analogues that were tested in intracellular calcium and patch‐clamp assays on cultured cells exogenously expressing human or mouse PIEZO1 or mouse PIEZO2, physico‐chemical assays and wire myography assays on vein from mice in which there was genetic disruption of PIEZO1. Key Results A Yoda1 analogue (KC159) containing 4‐benzoic acid instead of the pyrazine of Yoda1 and its potassium salt (KC289) have equivalent or improved reliability, efficacy and potency compared to Yoda1 in functional assays. Tested against over‐expressed mouse PIEZO1 in calcium assays, potency order is KC289 (150)>KC159 (280)>Yoda1 (600) (EC50s in parentheses, nM). There is selectivity for PIEZO1 over other membrane proteins and the physico‐chemical properties are more suited to physiological conditions than those of Yoda1. Vasorelaxant effects occur that are consistent with PIEZO1 agonism. 2‐benzoic acid substitution, by contrast, fails to generate a modulator. Conclusion and Implications 4‐Benzoic acid modification of Yoda1 improves PIEZO1 agonism. We suggest naming this new modulator Yoda2. It should be a useful tool compound in physiological assays and facilitate efforts to identify a binding site. Such compounds may have therapeutic potential, for example in diseases linked genetically to PIEZO1 such as lymphatic dysplasia.
pharmacology & pharmacy
What problem does this paper attempt to address?